Ann: US nursing home study to pave way for FDA De Novo clearance, page-14

Investment of biotech start-up stock is always due to fundamental, the fundamental haven't changed (in fact it actually got stronger with the acquisition but others think it's bad as they did the CR despite easily already having the cash before a very important clinical trial update). The SPP was actually very favourable to RI, the O/S of stocks isn't that important as others keeping mentioning as it all depend on the MC valuation, even after companies do a R/S the MC still remain the same doesn't it.

Painchek is based on APS except for the 1 of the 5 assessments which is the facial assessment so why there won't be a near 100% accuracy compared to the manual assessments. The issue with Painchek is still what they are experiencing with over 40% of the RCA market here where APS used and especially the global market where APS isn't used less, does it offer enough of a point of difference for RCA to change their current process, hence is digitialisation enough which has been PCK's selling point (clearly some RCA do find this useful but not a majority of them right now).